The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure
ClinicalTrials.gov · NCT06027567 · Registry updated: 2026-02-27
- Condition / research focus
- Idiopathic Intracranial Hypertension; Intracranial Pressure; Obesity; Pseudotumor Cerebri Syndrome; Papilledema; Weight Loss
- Sponsor
- Rigmor Højland Jensen
- Countries with listed sites
- Denmark
- Registry dates and results
- Start: 2022-09-02. Completion: 2025-10-28 (may be estimated). No results posted in this registry response.
Products and interventions (3)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Semaglutide (drug) — also listed as: Ozempic, Wegovy
- Very Low Calorie Diet (dietary_supplement)
- Dietician counselling (behavioral)
Where the study takes place — 2 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.